Nivolumab/Ipilimumab in Second Line CUP-syndrome

Summary

To compare the efficacy of nivolumab plus ipilimumab in subjects with high vs. Intermediate/low TMB poor-prognosis CUP (non-specific subset) who are relapsed or refractory to platinum-based first-line chemotherapy. To evaluate the efficacy of nivolumab plus ipilimumab in subjects with poor-prognosis CUP (non-specific subset) who are relapsed or refractory to platinum-based first-line chemotherapy

Timeline

Start

2019-12-12

Primary completion

2022-12

Completion

2022-12

Outcome

Missed primary endpoint

paper Although the primary endpoint was not met PMID 37875494 ↗

Publications

• Pouyiourou M, Kraft BN, Wohlfromm T, Stahl M, Kubuschok B, Loffler H, Hacker UT, Hubner G, Weiss L, Bitzer M, Ernst T, Schutt P, Hielscher T, Delorme S, Kirchner M, Kazdal D, Ball M, Kluck K, Stenzinger A, Bochtler T, Kramer A. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nat Commun. 2023 Oct 24;14(1):6761. doi: 10.1038/s41467-023-42400-5.

Drugs

Indications